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Abstract: The quantity and quality of dietary lipids in infant formulae have a significant impact on
health outcomes, especially when fat storing and/or absorption are limited (e.g., preterm birth and
short bowel disease) or when fat byproducts may help to prevent some pathologies (e.g., atopy).
The lipid composition of infant formulae varies according to the different fat sources used, and
the potential biological effects are related to the variety of saturated and unsaturated fatty acids.
For example, since lipids are the main source of energy when the normal absorptive capacity of the
digestive tract is compromised, medium-chain saturated fatty acids might cover this requirement.
Instead, ruminant-derived trans fatty acids and metabolites of n-3 long-chain polyunsaturated fatty
acids with their anti-inflammatory properties can modulate immune function. Furthermore, dietary
fats may influence the nutrient profile of formulae, improving the acceptance of these products and
the compliance with dietary schedules.
Keywords: fatty acids; infant formulae; preterm infants; short bowel disease; atopy
1. Introduction
Dietary lipids are the main source of energy in infants: they account for 45–55% of the total energy
provided by human milk and formula in the first six months of life [1]. Furthermore, they are involved
in the regulation of cell functions, in inter- and intracellular communication, and in the epigenetic
modulation of the genome [2]. The anatomical and functional development of the nervous system
seems particularly to depend on the direct supply of DHA and also ARA to some extent (not yet
defined) [1,3].
Consequently, the quality of dietary lipids in infant formulae has a significant impact on health
outcomes. In infants with limited stores of fats (such as preterms) and/or limitations on fat absorption
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(such as infants undergoing bowel resection), both the quantity and quality of supplied fats may
become more critical, considering the whole nutritional balance. The same considerations apply to
disorders where proinflammatory byproducts of some fatty acids have a proven pathogenic role
(such is the case with atopy). Therefore, a reappraisal of function and roles of different fat families
is relevant to derive indications for formulae fat composition, not just for healthy growing infants,
but infants with some specific disorders, to support either normal development while improving the
basal, non-physiologic condition.
2. Lipid Quality and Role in Human Milk and Infant Formulae
Triacylglycerols (TAGs) represent the 98–99% of total fats of human milk and infant formulae.
Their properties are devoted from the length and the insaturation grade of the fatty acids (FAs)
esterified to the glycerol backbone (Figure 1).
Figure 1. Lipid quality.
While in human milk the FA composition is dynamic and modulated by maternal diet, in formulae
the lipid content is fixed and derived from the vegetable oils [4], fish oils, algae oils, fractionated
lipids, and egg phospholipids used as ingredients. The use of dairy fats in infant formulae, even if it
has generally decreased, is still popular in some parts of the world [4] and has recently been given
attention [5] for some favorable metabolic effects.
2.1. Saturated and Monounsaturated Fatty Acids
Saturated fatty acids (SFAs) are abundant in human milk, making up a remarkable 10–12% of
the total dietary energy provided by palmitic acid (16:0) [2]. About 70% of the palmitic acid in human
milk is esterified to the sn-2 position of TAGs and, since the human lipases hydrolyses dietary TAGs at
the sn-1,3 position, palmitic acid is mainly absorbed as glycerol–palmitate [6]. This consideration is
important for infant formulae whose lipids are from palm oil, where palmitic oil, once hydrolyzed
in bowel lumen, tends to generate insoluble calcium soaps and negatively influences early bone
accretion [6].
Human milk contains small amounts of short-chain SFAs (SCFAs, with a carbon chain
length < 6C), and 8–10% of medium-chain SFAs (MCFAs, usually with a carbon length of 6–10C) [6].
TAGs containing SCFAs, MCFAs, and to some extent also lauric acid (12C), are more rapidly hydrolyzed
by gastrointestinal lipases without the need for bile salts, and their products are more easily absorbed
and taken directly to the liver via the portal vein. The ingestion of these FAs, therefore, could provide
some benefits under conditions where fat absorption is a limiting factor to reach adequate energy
supply [7–10]. Accordingly, in preterm infants, because of intestinal immaturity, facilitation of fat
absorption through the inclusion of MCFAs in the diet might be a promising approach. Yet, there is no
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demonstrated benefit for energy balance or growth in these patients. On the other hand, the addition
of dietary medium-chain triglycerides (MCTs) has been shown to be beneficial in children with severe
fat malabsorption such as short bowel syndrome, cystic fibrosis, or severe cholestatic liver disease [8].
Monounsaturated fatty acids (MUFAs) are, along with SFAs, the most represented fatty acid
family in human milk and infant formulae, and among them, oleic acid (OA, 18C:1 n-9) is by far the
most abundant. In the breastmilk of mothers from Mediterranean countries, where consumption of
olive oil is high, OA may reach levels higher than 40%, and total monounsaturated FA higher than
45%, respectively, of total FA in human milk [6].
The longest SFA represent the circulating pool for oxidation. Stearic acid (C18:0) may rapidly be
converted to OA, and this pathway indicates the strict metabolic interrelationships between the SFA
and the MUFA pool, respectively.
2.2. Polyunsaturated Fatty Acids
The human enzymatic machinery is not able to endogenously introduce a double bond in the
FA molecule at position n-6 and n-3. Therefore, the n-6 and n-3 FAs (6C and 3C, respectively, from
the methyl terminal), progenitors linoleic acid (LA, C18:2 n-6) and alpha-linolenic acid (ALA, C18:3
n-3), respectively, must be provided with the diet and are therefore named essential fatty acids (EFAs).
Both LA and ALA are metabolized by the same desaturases and elongases to longer and, more
unsaturated FAs (Figure 2). The n-6 FA cannot be converted to n-3 FA and vice versa.
Figure 2. Polyunsaturated fatty acids (n-6 and n-3).
In case of deficiency of the EFAs the same enzyme system starts to synthetize a non-essential 20C
polyunsaturated fatty acid (PUFA) from MUFA (eicosatrienoic acid, ETE, C20:3 n-9), not relevant from
the metabolic standpoint, whose levels are the major indicator of EFA deficiency [11].
The long-chain (LC) PUFAs (with chain length > 18C) include γ linolenic acid (GLA, C18:3 n-6),
dihomogamma linolenic acid (DHGLA, C20:3, n-6) and arachidonic acid (ARA, C20:4, n-6) for the n-6
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series and eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3) for the
n-3 series, respectively [12].
For the abovementioned reasons, the PUFAs composition of human milk primarily, but not only,
depends on the mother’s diet. As a matter of fact, breastmilk from vegans shows a high content of
LA and ALA, while that from mothers with a high dietary intake of fish has a high content of EPA
and DHA [6]. The circulating levels of DHA have been associated to the neurological, visual and IQ
performance [7]. The concentrations of DHA in breastmilk are also influenced by polymorphisms in
the fatty acid desaturase (FADS) gene cluster [7]. It has to be mentioned that a small amount of PUFA
is endogenously synthetized. This amount varies in people with common or uncommon variants of
the genes for these enzymes [4].
In infant formulae, LC-PUFAs are provided by adding fish oil, DHA-rich algal oil
from Crypthecodinium cohnii or ARA-rich fungal oil from Mortierella alpina, and phospholipids
(lecithin/phosphatidylcholine) from egg yolk [7].
Some of the most potent effects of PUFAs are related to their enzymatic conversion into a series of
oxygenated metabolites termed eicosanoids, so called because their precursors are PUFAs with chain
lengths of 20 carbon units. Eicosanoids modulate cardiovascular, pulmonary, immune, reproductive,
and secretory functions through organ systems in the human body. Eicosanoids are essential for all the
functions of human life and include prostaglandins (PG), thromboxanes (TXA), and leukotriene (LT)
from DHGLA, ARA, and EPA via cyclooxygenase and lipoxygenase pathways [13].
According to most epidemiological studies, an excess of dietary LA and/or ARA within the n-6
series compared to n-3 parental or derivate byproducts may support stronger proinflammatory and
allergic reactions due to the biological differences among n-6 and n-3 derived eicosanoids, respectively.
Therefore, as for the case of formulae to be used in preterm infants or those with small bowel syndrome,
the ratio n3/n6 LCPUFA should be closer to that of breastmilk with respect to standard formula [8,10].
2.3. Trans Fatty Acids
Trans fatty acids (TFAs) include unsaturated and polyunsaturated fatty acids with at least one
double bond in trans configuration [14].
Dietary TFAs may come from two sources. Firstly, non-natural source includes the industrial
production, by means of partial hydrogenation of vegetable oils (e.g., elaidic acid, C18:1, trans-9).
Secondly, as natural sources, they mainly derive from ruminant-derived foods (e.g., vaccenic acid
(VA, C18:1, trans-11) and rumenic acid (RA, C18:2, cis-9, trans-11), VA is one of the most abundant
TFAs in breast and cow’s milk and also dairy products. It is the intermediary precursor of RA,
a conjugated linoleic acid (CLA) compound produced by bacterial biohydrogenation of FAs in the
rumen of ruminant livestock like cows [14] (Figure 3). RA and VA in breastmilk originate mainly from
dietary ruminant fat and the main source of ruminant fat in the diet is dairy fat, and to a smaller extent
ruminant meat.
Clinical evidence indicates that natural TFAs have properties distinct from those of synthetically
produced partially hydrogenated vegetable oils [14].
Wijga et al. [15] showed that a higher concentration of trans FA in breastmilk is associated with
lower risk of atopic symptoms. Thijs et al. [16] confirmed these observations in children, by showing a
protective association (with a plausible cause–effect relationship) of these FAs on the development of
atopic manifestations. Chisaguano et al. [14] showed that higher maternal VA concentrations at week
12 of gestation were associated with a decreased risk of atopic eczema in one-year-old infants.
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Figure 3. Natural trans fatty acids.
Mechanisms through which CLAs modulate immune function include influences on the
production of cytokines, eicosanoids (prostaglandins, leukotrienes) and nitric oxide, inhibition of
eosinophilic cationic protein, decreased availability of ARA or inhibition of either cyclooxygenase
and mRNA expression of phospholipase A2, NFkappaB DNA-binding activity, and binding to
PPAR-gamma [14].The EFSA Panel considers the current specifications for TFAs content in infant
formulae and follow-on formulas as < 3 FAs % to be adequate [7].
3. Fats in Infant Formulae Intended for Medical Condition (According to the Regulation
Eu n. 609/2013)
3.1. Preterm Formulae
Lipids in preterm formulae provide the infant with the majority of energy, and the LC-PUFA
(Table 1). In particular, the availability and metabolism of LC-PUFAs have direct implications for cell
membrane functions and the formation of bioactive eicosanoids [17]. The supply of LC-PUFAs to the
fetus during gestation is actively provided by maternal plasma. Thus, the preterm infant receives fewer
LC-PUFAs prior to birth than a full-term infant and, therefore has a higher LC-PUFAs requirement
at birth. Preterm babies lack of the so-called period of “biomagnification” when in late gestation the
maternal supply of LC-PUFA progressively increases [18]. Accordingly, their daily needs per kilogram,
or per 100 kcal, are greater in early life [19].
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Preterm infant formulae are currently supplemented with commercially available sources of
LC-PUFAs so that the fatty acid composition could be as similar as possible to human milk, but probably
the supply of DHA and ARA should even be higher [19]. Most oils added to infant formulae are
derived exclusively from microorganisms, others are derived both from a combination of low-EPA fish
oil and microorganisms, sources of DHA and ARA, respectively. The usual DHA content of preterm
formulae ranges between 0.2% and 0.4% of total FAs [20].
Since the coefficient of fat absorption decreases with the FAs chain length and increases with the
number of double bonds, a high concentration of MCTs have been used in some preterm formulae
to increase the coefficient of fat absorption in preterm infants [21]. The immaturity of digestive tract
and high demand for energy further support the use of MCTs in preterm infants [21,22]. However,
the MCTs content in preterm formulae should not exceed 40% of the total fats, [17] to avoid the
increase of formula osmolality [23]. However, this is not broadly agreed. There is no evidence
that either a deficiency or an excess of LA in preterm formulae is associated with adverse effects.
However, LA intake between 385 and 1540 mg−1 kg−1 day−1 or between 350 to 1400 mg/100 kcal
(3.2–12.6 E %) is currently considered acceptable. Both AA and DHA should be included in preterm
formulae, and oils containing significant amounts of EPA should be avoided to prevent interference
with the growth-promoting effects of ARA [24]. Recommended intakes are 12–30 mg−1 kg−1 day−1 or
11–27 mg/100 kcal for DHA and 18–42 mg−1 kg−1 day−1 or 16–39 mg/100 kcal for AA. The ratio of
AA to DHA should be in the range of 1.0–2.0 to 1 (wt/wt), and EPA supply should not exceed 30%
of DHA supply [17]. LC-PUFAs, added from fish oils or from single-cell algae, are actually added as
triglycerides to the fat blend of preterm formulae [20]. The addition of DHA and ARA as enriched
PL from egg yolk is maybe too expensive, even if it was found effective in the 1990s for enriched
term-infant formulae [25].
Therapeutic formulae for preterms contain around 50% energy from fat, out of which up to 55%
is obtained from MCTs, which allows for an appropriate proportion of essential fatty acids (EFAs), too.
The usual DHA content of preterm formulae ranges between 0.2% and 0.4% of total FA [26].
A beneficial effect of the LC-PUFA supplementation in preterm formulae on neurological functions
has not been demonstrated by meta-analyses so far. This may be due to the high variability in study
designs and to the inclusion in the studied cohorts of relatively mature and mildly preterm infants,
who are likely less DHA-deficient than extremely premature babies [20].
Moreover, the amount of LC-PUFAs used in early studies was chosen to produce the same
concentration of ARA and DHA of the breastmilk (i.e., 0.2–0.4% fatty acids). This may not be an
appropriate approach for preterm infants since the amount of DHA provided by breastmilk is below
the accretion rate in utero. Indeed, infants fed with these formulae have constantly exhibited a reduced
DHA status at time of discharge of hospital or expected term [20]. Several studies report outcome data
in preterm infants fed with milk containing a high DHA content of 0.5–1.7% of total FAs. The first
study that examined the effect of providing DHA supplementation (0.50% of total fatty acids) for
up to nine months after term, showed that DHA improved growth in the whole cohort of preterm
infants and improved mental development in boys [27]. Three out of six reports of preterm infants
fed preterm formulae supplemented with n-3, but not n-6 LC-PUFAs showed some indices of lower
growth [20]. Since then, all trials have investigated the effects of n-3 LC-PUFAs supplementation in
preterm formulae together with ARA supplementation and none has demonstrated a negative effect of
supplementation on growth [20]. Hence, the benefit of ARA supplementation is debated and, in any
case, restricted to term infants [3].
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Table 1. Lipid composition of the principal available infant formulae for preterms.
Formula Fat(% En tot)
TFA
(g)
Saturated
(g)
MUFAs
(g)
PUFAs
(g)
MCTs
(g)
LA
(mg)
ALA
(mg)
EPA
(mg)
ARA
(mg)
DHA
(mg)
Pre Nidina ospedale (100 mL) 44.4 4 1.7 1.6 560 80 16 16
Pre Nidina casa (100 mL 14.4% w/v) 46.8 3.8 1 373.1 75.2 14.1 14.4
Pre-Humana (100 mL 13.5% w /v) 43.6 3.2 1.1 1.5 0.7
Humana 0 (100 mL 15.4% w/v) 46.7 4 1.4 1.8 0.9 739 80 17.6 17.6
Humana 0-VLB (100 mL 15.4% w/v) 41.7 3.9 1.3 1.9 0.7 0.6 549 69 21.5 21.5
Plasmon Pre-0 (100 mL) 46 4.2 0.8 25.1 14.7
Plasmon 0 (100 mL) 44.4 3.9 1.6 1.4 0.9 0.6 770 100 23.2 13.5
Mellin 0 43.8 3.9 0.2 2.9 17.7 13.6
Mellin 0 POST (100 mL al 15.5% w/v) 48 4 1.7 1.7 0.7 0.8 513 71 2.5 17 13
Formulat Pre-0 (100 ml) 44.5 4.1 1.25 1.7 0.8 670 97 28 21.5
Formulat 0 (100 mL) 45 4.1 1.4 1.7 0.8 670 97 24.6 21.3
Pre- Aptamil (100 mL 14.4% w/v) 48 4 1.5 1.8 0.6 0,8 490 76.7 2.3 17.4 13.2
Similac 24 (100 mL) 48.8 4.4 568 8 8
Miltina 0 (100 mL) 48 4 1.1 8 8
Miltina 0 post (100 mL) 48 4 0.8 2.5 17 13
Blemil Plus (100 mL 15.9% w/v) 45.5 4.1 0.5 611 49 24.6 16.4
Eveil formula 0 (100 mL) 45 4.1 0.6 24 12
Nutribén Pre (100 mL) 48.3 4.3 0.4 20 20
TFA: Trans fatty acids; MUFAs: monounsaturated fatty acids; PUFAs: polyunsaturated fatty acid; MCTs: medium-chain triglycerides; LA: linoleic acid; ALA: alpha-linolenic acid;
EPA: eicosapentaenoic acid; ARA: arachidonic acid; DHA: docosahexaenoic acid; Data in Tables adapted from De Curti M et al. [28].
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3.2. Short Bowel Syndrome
Short bowel syndrome (SBS) is a subcategory of intestinal failure, which may result from large
resection of jejunum or ileum, and is associated with significant malabsorption. This condition is
characterized by the inability to maintain adequate protein-energy, fluid, electrolyte, or micronutrient
retention with a conventionally accepted, balanced diet. The clinical manifestation of SBS is determined
by different variables such as the residual length of the jejunum and ileum, ostomies and their location,
the presence (or absence) of the ileocecal valve, the remaining functional and absorptive length of the
colon, underlying pathology and possible complications. After resection, the remaining portion of the
intestine attempts to compensate for the lower efficiency of fluid and nutrient absorption, evolving
through hypertrophy and muscular hyperplasia. Enteral nutrition plays an important trophic role
per se, since the intraluminal nutrients may stimulate the epithelial cells and the production of tropic
hormones [29].
Other available strategies for the clinician include absorptive adaptive and motility strategies
needed to achieve successful intestinal rehabilitation in SBS. Even if in most SBS infants, feeding
strategies alone are not sufficient to overcome the constraints of a reduced intestinal surface area to
meet nutrient requirements, elemental or semi-elemental formulae, and continuous drip feeding are
described to be successful [30–32]. The composition of main formulae available in Italy is showed in
Table 2.
The switch towards the enteral nutrition of infants with SBS may be advantageous while
decreasing the provision of an adequate caloric supply, so the pros and cons should be carefully
evaluated on a case-by-case basis. The addition of fats, in the form of either LCTs or MCTs, to formulae
is more frequent than that of carbohydrates or proteins since effects on formula osmolality are
minimal [31].
LCTs undergo bile-dependent hydrolysis in the proximal bowel. The ileal and jejunal
chemoreceptors detect the presence of long-chain FAs (LCFAs) and stimulate the secretion of PYY (YY
Peptide) and GLP2 (Glucagon-like peptide-2). The latter mediates the phenomenon of the ileal and
jejunal brake, which consists of the slowing of the proximal intestinal transit. LCTs also stimulate CCK
(CholeCystoKinin) release, slowing gastric emptying. These entero-endocrine signals are studied for
their potential trophic benefits, as well. N-3 LC-PUFAs were also shown to have anti-inflammatory
effects while improving splanchnic circulation and cholestasis in these patients [8]. In a randomized
controlled trial, using an n-6 based source of LCTs with an n-3 supplement to maintain appropriate
ratios, preliminary results show positive effects on growth, feeding tolerance, and fecal consistency [31].
The digestive and metabolic properties of MCFAs, already mentioned in the previous sections,
may be highlighted in SBS patients, and therefore formulae containing 40–60% MCTs with remainder as
LCTs appear to be not only well tolerated but indicated for nutritional rehabilitation and maintenance.
For clinical applications, some investigators suggested that the type of fats to be administered should
be based on the remaining bowel length and capacity, surgical history and the probability of fat
malabsorption secondary also to the lack of adequate concentrations of luminal bile acids [31]. In these
patients, MCTs improved total fat and energy absorption [33]. This might be explained by considering
that the colon serves as a digestive organ for energy salvage (CHO metabolism and MCTs absorption)
and production of trophic factors, such as SCFAS [8].
If intolerance to additional LCTs occurs, MCTs might be a valid alternative, although MCT
oil, immiscible in feeds, has been associated with lipoid pneumonia. Accordingly, in infants with
esophageal abnormalities, vomiting, and/or severe reflux disease, caution is needed [31].
In spite of significant advances in the management of SBS in infants, further efforts are needed to
translate newer dietary manipulations into standards of practice for the SBS population and prevent
the widespread poor nutrition status in this population.
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Table 2. Lipid composition of the principal available infant formulae for SBS.
Formula Fat(% En tot)
TFA
Total (g)
Saturated
(g)
MUFAs
(g)
PUFAs
(g)
LCTs
(g)
MCTs
(g)
Omega-3
(g)
LA
(mg)
ALA
(mg)
Nutrients 2018, 10, x FOR PEER REVIEW  9 of 14 
 
Table 2. Lipid composition of the principal available infant formulae for SBS. 
Formula 
Fat 
(% En tot) 
TFA 
total (g) 
Saturated 
(g) 
MUFAs 
(g) 
PUFAs 
(g) 
LCTs 
(g) 
MCTs 
(g) 
Omega-3 
(g) 
LA 
(mg) 
ALA 
(mg) 
ɣ-LA 
(mg) 
ARA 
(mg) 
DHA 
(mg) 
EPA 
(mg) 
Elemental 028 extra * 36 3.5 1.35 1.6 0.45 2.275 1.225        
Monogen (100 mL 16.8% w/v) 26.5 2.2 1.9 0.4 1.3 0.35 1.85        
Peptamen Junior PHGG (100 mL) 32 3.6 2 0.5 1.1  1.5 0.16       
Alfaré (100 mL 13.5% w/v) 43 3.4 2.1    1.3  480 60 17  5.7  
Neocate LCP (100 mL 13.8% w/v) 46 3.4 1.2 1.3 0.66 3.26 0.136  579 57.8  11.3 11.3  
Infatrini Peptisorb (100 mL 14% w/v) 49 5.4 3.4    2.7  421 83.9  15.8 15.7  
Nutrini Peptisorb (100 mL 15% w/v) 35 3.9 2.2 0.5 1.2  1.8  1010 92.7     
Humana Disanal (100 mL 14.5% w/v) 29.5 2.1 0.8 0.9 0.4    374 53     
Aptamil- pepti Junior (100 mL 12.8% w/v) 47.7 3.5 1.9 0.81 0.6 0.02 1.71  486.5 94.85 0.35 7 7 1.4 
Pantolac 1 (100 mL 13.7% w/v) 46.4 3.4 1.5 1.3 0.5    418 84  11 6.4 1.4 
Pantolac 2 (100 mL 13.8% w/v)  40.3 3 1.4 0.517 0.05    7.9 4.4     
Vivonex Pediatric (100 mL 22% w/v) 30.4 2.7     1.8  382      
* Oral formula only; Data in Tables adapted from De Curti M et al. [28]. 
 
-
( g) ( g)
DHA
(mg)
EPA
(mg)
Elemental 028 extra * 36 3.5 1.35 1.6 0.45 2.275 1.225
Monogen (100 mL 16.8% w/v) 26.5 2.2 1.9 0.4 1.3 0.35 1.85
Peptamen Junior PHGG (100 mL) 32 3.6 2 0.5 1.1 1.5 0.16
Alfaré (100 mL 13.5% w/v) 43 3.4 2.1 1.3 480 60 17 5.7
Neocate LCP (100 mL 13.8% w/v) 46 3.4 1.2 1.3 0.66 3.26 0.136 579 57.8 11.3 11.3
Infatrini Peptisorb (100 mL 14% w/v) 49 5.4 3.4 2.7 421 83.9 15.8 15.7
Nutrini Peptisorb (100 mL 15% w/v) 35 3.9 2.2 0.5 1.2 1.8 1010 92.7
Humana Disanal (100 mL 14.5% w/v) 29.5 2.1 0.8 0.9 0.4 374 53
Aptamil- pepti Junior (100 mL 12.8% w/v) 47.7 3.5 1.9 0.81 0.6 0.02 1.71 486.5 94.85 0.35 7 7 1.4
Pantolac 1 (100 mL 13.7% w/v) 46.4 3.4 1.5 1.3 0.5 418 84 11 6.4 1.4
Pantolac 2 (100 mL 13.8% w/v) 40.3 3 1.4 0.517 0.05 7.9 4.4
Vivonex Pediatric (100 mL 22% w/v) 30.4 2.7 1.8 382
* Oral formula only; Data in Tables adapted from De Curti M et al. [28].
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3.3. Atopic Disorders
Formulae based on partial (Hypoallergenic—HA formulas) or extensively hydrolyzed proteins
(eHF) (mostly cow’s milk proteins, casein and whey, or vegetable proteins, mostly rice and soy), amino
acid formulae (AAF), and milk from other mammals represent the dietary options available for the
treatment (or even prevention) of cow’s milk allergy (CMA) [34] (Table 3).
Recently, instead of total avoidance of the offending compounds, new proactive dietary habits
have been developed. Since food allergy results when there is a breakdown or the oral “tolerance”
mechanisms, which leads to inappropriate immune responses to ordinary food allergens, it has been
hypothesized that some nutrients, such as EFAs (and even the offending allergens), could positively
influence this process [35].
Within this context, the fat quality in the formula becomes critical, since eicosanoids are
key players in the mechanism of atopic disorders. The modulation of the LA/ALA ratio and
their LC derivatives may offer the opportunity to balance the synthesis of their pro-inflammatory
and pro-allergic lipid products, the eicosanoids, and the DHA-derived mediators (resolvins and
protectins) [36].
The fat-associated dietary modulation may have direct effects on the inflamed gastrointestinal
tract of atopic and food-allergic infants [37]. Inflammation may be viewed as a byproduct of the
metabolic activity of gut microbiota from evidence that SCFAs are altered in overweight or atopic
children [38].
More recently, the SCFAs acetate, butyrate, and propionate have attracted interest as mediators
of allergic inflammations. They are produced by gut microbes and are used as an energy source
by intestinal epithelial cells; after absorption, they may be easily utilized by the liver to increase
gluconeogenesis [39]. Fatty acids can also play a strategic role in influencing the sensory profile of
formulae for infants with CMA. In clinical practice both eHF and AAF are frequently rejected by
children because of the taste. The unpleasant flavor of hydrolysis byproducts has been related to
the peptides released during proteolytic processes, but recent observations suggest that palatability
may improve, for instance, by manipulating levels of lactose and some FAs [40]. Oral fat exposure
initiates cephalic phase responses throughout and beyond the gastrointestinal (GI) tract. To date,
documented effects include: gastric lipase secretion, modulated GI transit, pancreatic exocrine
secretions, gut hormone release, mobilization of stored lipid from enterocytes, pancreatic endocrine
secretion, and altered lipoprotein lipase activity. As a consequence, dietary fats may influence
appetitive responses, food intake, and nutritional status as a whole [40].
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Table 3. Lipid composition of the principal available infant formulae for atopy.
Formula Fat(% En tot)
TFA
(g)
Saturated
(g)
MUFAs
(g)
PUFAs
(g)
LCTs
(g)
MCTs
(g)
LA
(mg)
ALA
(mg)
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Formula 
Fat 
(% En tot) 
TFA 
total (g) 
Saturated 
(g) 
MUFAs 
(g) 
PUFAs 
(g) 
LCTs 
(g) 
MCTs 
(g) 
Omega-3 
(g) 
LA 
(mg) 
ALA 
(mg) 
ɣ-LA 
(mg) 
ARA 
(mg) 
DHA 
(mg) 
EPA 
(mg) 
Elemental 028 extra * 36 3.5 1.35 1.6 0.45 2.275 1.225        
Monogen (100 mL 16.8% w/v) 26.5 2.2 1.9 0.4 1.3 0.35 1.85        
Peptamen Junior PHGG (100 mL) 32 3.6 2 0.5 1.1  1.5 0.16       
Alfaré (100 mL 13.5% w/v) 43 3.4 2.1    1.3  480 60 17  5.7  
Neocate LCP (100 mL 13.8% w/v) 46 3.4 1.2 1.3 0.66 3.26 0.136  579 57.8  11.3 11.3  
Infatrini Peptisorb (100 mL 14% w/v) 49 5.4 3.4    2.7  421 83.9  15.8 15.7  
Nutrini Peptisorb (100 mL 15% w/v) 35 3.9 2.2 0.5 1.2  1.8  1010 92.7     
Humana Disanal (100 mL 14.5% w/v) 29.5 2.1 0.8 0.9 0.4    374 53     
Aptamil- pepti Junior (100 mL 12.8% w/v) 47.7 3.5 1.9 0.81 0.6 0.02 1.71  486.5 94.85 0.35 7 7 1.4 
Pantolac 1 (100 mL 13.7% w/v) 46.4 3.4 1.5 1.3 0.5    418 84  11 6.4 1.4 
Pantolac 2 (100 mL 13.8% w/v)  40.3 3 1.4 0.517 0.05    7.9 4.4     
Vivonex Pediatric (100 mL 22% w/v) 30.4 2.7     1.8  382      
* Oral formula only; Data in Tables adapted from De Curti M et al. [28]. 
 
-
( g) ( g)
EP
( g)
DH
( g)
Mellin Polilat 1 (100 mL 13.6% w/v) 47 3.5 1.6 1.3 0.6 455 83 12 2.3 11
Mellin Polilat 2 (100 mL 14.4% w/v) 41 3.1 1.4 1.2 0.5 411 75 9 1.9 9
Nidina H.A 1 (100 mL 13.1% w/v) 45.7 3.4 1 536 65 7.8 7.8
Nidina H.A 2 (100 mL 13.6% p/v) 41.6 3.1 0.8 0.6 466.6 57 5.7 5.7
Althéra (100 mL 13.2% w/v) 45.6 3.4 1.3 500 50 7.4 7.4
Alfaré (100 mL 13.5% w/v) 43 3.4 1.3 480 60 5.7
Pregestemil Lipil (100 mL) 50.3 3.8 2.1 23 11.5
Neocate Spoon (100 g powder) 36 18.8 6.9 7.5 3.5 18 0.8 3222 322
Neocate LCP (100 mL 13.8% w/v) 46 3.4 1.2 1.3 0.66 3.3 0.1 579 57.8 11.3 11.3
Neocate Junior (100 mL 21.1% w/v) 42 4.6 2 1.6 0.84 1.61
Humana AT 1 (100 mL 14% w/v) 46.9 3.6 1.4 1.4 0.7 595 52 13 13
Humana AT 2 (100 mL 13.4% w/v) 46.4 3.4 1.4 1.3 0.6 569 50 0.7 13 13
Aptamil pepti 1 (100 mL 13.6% w/v) 47 3.5 1.9 1.29 0.62 2.73 0.13 479.5 87.85 16.8 12 2.45 11
Aptamil pepti 2 (100 mL 14.4% w/v) 41 3.1 1.4 1.14 4.36 2.41 0.11 479.5 87.85 0.7 9 2.1 9
Data in Tables adapted from De Curti M et al. [28].
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4. Conclusions
Since dietary fats are not only a source of energy but might also impact on health
outcomes, the lipid composition of infant formulae is fundamental, particularly in children with
special requirements.
In particular, the different types of fat may be crucial for the nutrition of preterm, short bowel,
and atopic infants. Accordingly, MCTs can help to cover energy needs when the normal absorptive
capacity of the digestive tract is compromised, while TFAs and metabolites of n-3 LC-PUFAs with their
anti-inflammatory properties can modulate the immune function. Finally, the modification of taste
by different fat types is a further issue requiring careful attention to improve the acceptance of these
special products and compliance with therapeutic schedules.
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